AMA Urges FTC to Act on Insulin Prices
[from AMA Advocacy Update]
The AMA expressed strong concern to the Federal Trade Commission (FTC) in an Oct. 26 letter
about the sharp rise in insulin prices among manufacturers. The AMA
urged the agency to monitor insulin pricing and assess whether
anti-competitive actions were driving higher insulin prices.
The AMA asked that the FTC recommend enforcement action against
manufacturers that were engaged in anti-competitive practices to the
U.S. Department of Justice. In the letter, the AMA cited lawsuits filed
in 2017 against insulin manufacturers on behalf of patients that noted
there were "rapid and lockstep price increases of more than 150
percent."
In addition,Modern
Healthcare (11/1, Luthi, Subscription Publication) reports that Reps. Tom
Reed (R-NY) and Diane DeGette (D-CO) are asking Congress “to limit patent
extensions which have allowed insulin manufacturers to stop new generics from
entering the market” in order to address rising insulin costs. According to
their analysis, “Experts predict that follow-on insulins could cost 20 to 40
percent less than their brand name equivalents, creating savings for patients.”
The article says other proposed changes include a proposal for “PBMs and health
plans to disclose how many rebates they receive and pass along,” as well as
“banning the ‘pay-for-delay’ practice in which the expired patent-holding brand
drug maker pays a generic manufacturer not to produce the off-patent drug.”
< Previous Article |
Next Article >
[ return to top ]
|